A. Xu

发表

Expression Level and Clinical Significance of NKILA in Human Cancers: A Systematic Review and Meta-Analysis

Yang Yu, Hu Xu, Yuan Zhou, 2020, BioMed research international.

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

F. Chen, Ping Yang, He-long Zhang, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA2 Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2

Minhu Chen, Zhengming Chen, G. Shao, 2020 .

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Ping Yang, He-long Zhang, H. Pan, 2020 .

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

W. Fang, Li Xu, H. Pan, 2020 .

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

Ying Cheng, W. Fang, Jianming Xu, 2021, The lancet. Gastroenterology & hepatology.

Long noncoding RNA ANRIL promotes the malignant progression of cholangiocarcinoma by epigenetically repressing ERRFI1 expression

Lei Yang, Qiaoyu Chen, Jian Yang, 2020, Cancer science.

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.

Jinhai Wang, F. Xia, Y. Mao, 2021, The Lancet. Oncology.

Development and Validation of Nomograms to Predict the Prognosis of Patients With Unresectable Hepatocellular Carcinoma Receiving Transarterial Chemoembolization

W. Ding, Caifang Ni, Dongxu Zhao, 2023, Clinical Medicine Insights. Oncology.

Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study.

Wei Li, S. Chan, Z. Meng, 2023, Journal of Clinical Oncology.

Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma.

G. Shao, S. Jiao, Xiaoping Jin, 2021 .

Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study.

Xiao‐Yu Yin, Wei Li, Yufeng Cheng, 2023, Journal of Clinical Oncology.

The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial

G. Shao, Y. Bai, Baiyong Li, 2023, Frontiers in immunology.

A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394

Shuangyan Ou, A. Xu, Shukui Qin, 2024, Liver cancer.